08/08/22 4:03 PMNasdaq : ENTA earningslow floatEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ETEnanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2022. We look forward to initiating a Phase 2 study in the fourth quarter of this year,” said Jay R. Luly, Ph.D., President and Chief...RHEA-AIneutral
08/08/22 4:00 PMNasdaq : ENTA managementlow floatEnanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical OfficerEnanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. Scott T. Rottinghaus, M.D., Senior Vice President and...RHEA-AIvery positive
08/01/22 7:00 AMNasdaq : ENTA conferencesearningslow floatEnanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2022 after the U.S. market closes on August 8, 2022. A replay of the conference call will be...RHEA-AIneutral
07/29/22 7:00 AMNasdaq : ENTA clinical trialcovid-19low floatEnanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics of orally administered single ascending doses and multiple ascending doses of...RHEA-AIpositive
06/21/22 4:50 PMNasdaq : ENTA low floatEnanta Pharmaceuticals Files Patent Infringement Suit Against PfizerEnanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, announced today that it has filed suit in United States District Court for the District of Massachusetts against Pfizer, Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 in the...RHEA-AIneutral
06/08/22 7:00 AMNasdaq : ENTA low floatEnanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’ s internal development program portfolio for hepatitis B virus and its out-licensing program portfolio for non-alcoholic steatohepatitis have been accepted...RHEA-AIneutral
06/02/22 7:00 AMNasdaq : ENTA conferenceslow floatEnanta Pharmaceuticals to Participate in Two Investor Conferences in JuneEnanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two fireside chats being webcast in June:. Jefferies Healthcare Conference: Fireside Chat at 9:00 a.m. ET...RHEA-AIneutral
05/18/22 4:01 PMNasdaq : ENTA acquisitionlow floatEnanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported topline results for RSVP, its Phase 2 b study evaluating EDP-938, a potent N-protein inhibitor, in otherwise healthy adults with community-acquired RSV. The effect on RSV RNA viral load is...RHEA-AIneutral
05/09/22 4:01 PMNasdaq : ENTA earningslow floatEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ETEnanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2022. “We had a strong start to 2022, making meaningful strides to advance our leadership in the development of therapeutics...RHEA-AIneutral
05/02/22 7:00 AMNasdaq : ENTA conferencesearningslow floatEnanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2022 after the U.S. market closes on May 9, 2022. To participate in the live conference call,...RHEA-AIneutral